Shots: Shots:

• The ongoing P-II study involves assessing Libtayo (300mg- IV- q3w) for up to 93 wks. or until disease progression- unacceptable toxicity- withdrawal of consent or confirmed complete response in 132 patients with advanced BCC who were intolerant to prior HHI therapy
• The P-II study results: ORR (29% in patients with LA disease) with an estimated DOR exceeding one year in 85% of responders; in a preliminary analysis- ORR (21% in patients with mBCC) with an estimated DOR exceeding one year in 83% of responders
• Libtayo is a mAb targeting the PD-1 on T-cells and acts by blocking the cancer cells from using the PD-1 pathway to suppress T-cell activation. Both the companies plan the regulatory submission of the therapy in 2020

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Money Control